Tedizolid phosphate for the management of acute bacterial skin and skin structure infections: Safety summary

Clinical Infectious Diseases

Volumn 58, Issue SUPPL. 1, 2014, Pages

  Das, Debaditya ^a   Tulkens, Paul M ^a   Mehra, Purvi ^b   Fang, Edward ^c   Prokocimer, Philippe ^c  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^b ECMC Department of Surgery   (United States)

^c Cubist Pharmaceuticals   (United States)

Author keywords

ABSSSI; clinical trials; safety; tedizolid phosphate; treatment emergent adverse events

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING); SEROTONIN; TEDIZOLID;

ARTICLE; BACTERIAL SKIN DISEASE; COMPARATIVE STUDY; DRUG DOSE INCREASE; DRUG SAFETY; ENZYME ACTIVITY; HUMAN; KIDNEY DISEASE; LIVER DISEASE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PREDICTION; PRESSOR RESPONSE; PRIORITY JOURNAL; SKIN INFECTION; SKIN STRUCTURE;

ABSSSI; CLINICAL TRIALS; SAFETY; TEDIZOLID PHOSPHATE; TREATMENT-EMERGENT ADVERSE EVENTS;

ANIMALS; ANTI-BACTERIAL AGENTS; CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; ORGANOPHOSPHATES; OXAZOLES; STAPHYLOCOCCAL SKIN INFECTIONS;

EID: 84892176282     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cit618     Document Type: Article

References (53)

1. May AK, Stafford RE, Bulger EM, et al.; Surgical Infection Society. Treatment of complicated skin and soft tissue infections. Surg Infect (Larchmt) 2009; 10:467-99
2. Stefani S, Chung DR, Lindsay JA, et al. Methicillin-resistant Staphylococcus aureus (MRSA): Global epidemiology and harmonisation of typing methods. Int J Antimicrob Agents 2012; 39:273-82
3. Shlaes DM, Spellberg B. Overcoming the challenges to developing new antibiotics. Curr Opin Pharmacol 2012; 12:522-6
4. Talan DA, Krishnadasan A, et al.; EMERGEncy ID Net Study Group. Comparison of Staphylococcus aureus from skin and soft-tissue infections in US emergency department patients, 2004 and 2008. Clin Infect Dis 2011; 53:144-9
5. Zervos MJ, Freeman K, Vo L, et al. Epidemiology and outcomes of complicated skin and soft tissue infections in hospitalized patients. J Clin Microbiol 2012; 50:238-45
6. Marra F, Patrick DM, Chong M, Mckay R, Hoang L, Bowie WR. Increased incidence of skin and soft tissue infections and associated antimicrobial use: A population-based study. Antimicrob Agents Chemother 2012; 56:6243-9
7. Kanafani ZA, Corey GR. Tedizolid (TR-701): A new oxazolidinone with enhanced potency. Expert Opin Investig Drugs 2012; 21:515-22
8. Shaw KJ, Barbachyn MR. The oxazolidinones: Past, present, and future. Ann N Y Acad Sci 2011; 1241:48-70
9. Viriese AS, Coster RV, Smet J, et al. Linezolid-induced inhibition of mitochondrial protein synthesis. Clin Infect Dis 2006; 42:1111-7
10. Lee M, Lee J, Carroll MW, et al. Linezolid for treatment of chronic extensively drug-resistant tuberculosis. N Engl J Med. 2012; 367:1508-18
11. Renslo AR. Antibacterial oxazolidinones: Emerging structure-toxicity relationships. Expert Rev Anti Infect Ther 2010; 8:565-74
12. Im WB, Choi SH, Park JY, Choi SH, Finn J, Yoon SH. Discovery of torezolid as a novel 5-hydroxymethyl-oxazolidinone antibacterial agent. Eur J Med Chem 2011; 46:1027-39
13. Reck F, Zhou F, Eyermann CJ, Kern G, et al. Novel substituted (pyridin-3-yl)phenyloxazolidinones: Antibacterial agents with reduced activity against monoamine oxidase A and increased solubility. J Med Chem 2007; 50:4868-81
14. Gu B, Kelesidis T, Tsiodras S, Hindler J, Humphries RM. The emerging problem of linezolid-resistant Staphylococcus. J Antimicrob Chemother 2013; 68:4-11
15. Lemaire S, Van Bambeke F, Appelbaum PC, Tulkens PM. Cellular pharmacokinetics and intracellular activity of torezolid (TR-700): Studies with human macrophage (THP-1) and endothelial (HUVEC)cell lines. J Antimicrob Chemother 2009; 64:1035-43
16. Prokocimer P, Bien P, Muñoz KA, Bohn J, Wright R, Bethune C. Human pharmacokinetics of the prodrug TR-701 and TR-700, its active moiety, after multiple oral doses of 200 to 400 mg TR-701, a novel oxazolidinone. Presented at: 48th Annual ICAAC/IDSA 46th Annual Meeting (ICAAC/IDSA 2008); 25-28 October 2008; Washington, DC. Poster F1-2064
17. Bien P, Prokocimer P, Muñoz KA, Bohn J. The safety of 21-day multiple ascending oral doses of TR-701, a novel oxazolidinone prodrug antibiotic. Presented at: 19th European Congress of Clinical Microbiology and Infectious Diseases; 16-19 May 2009; Helsinki, Finland. Poster P1089
18. Prokocimer P, Bien P, Muñoz KA, Aster R. Hematological effects of TR-701, linezolid and placebo administered for 21 days in healthy subjects. Presented at: 48th Annual ICAAC/IDSA 46th Annual Meeting (ICAAC/IDSA 2008); 25-28 October 2008; Washington, DC. Poster F1-2069a.
19. Gerson SL, Kaplan SL, Bruss JB, et al. Hematologic effects of linezolid: Summary of clinical experience. Antimicrob Agents Chemother 2002; 46:2723-6
20. Birmingham MC, Rayner CR, Meagher AK, Flavin SM, Batts DH, Schentag JJ. Linezolid for the treatment of multidrug-resistant, Gram-positive infections: Experience from a compassionate-use program. Clin Infect Dis 2003; 36:159-68
21. Vinh DC, Rubinstein E. Linezolid: A review of safety and tolerability. J Infect 2009; 599(Suppl 1):S59-74
22. Takahashi Y, Takesue Y, Nakajima K, et al. Risk factors associated with the development of thrombocytopenia in patients who received linezolid therapy. J Infect Chemother 2011; 17:382-387
23. Stahl SM, Felker A. Monoamine oxidase inhibitors: A modern guide to an unrequited class of antidepressants. CNS Spectr 2008; 13:855-70
24. Antal EJ, Hendershot PE, Batts DH, Sheu WP, Hopkins NK, Donaldson KM. Linezolid, a novel oxazolidinone antibiotic: Assessment of monoamine oxidase inhibition using pressor response to oral tyramine. J Clin Pharmacol 2001; 41:552-62
25. Hendershot PE, Antal EJ, Welshman IR, Batts DH, Hopkins NK. Linezolid: Pharmacokinetic and pharmacodynamic evaluation of coadministration with pseudoephedrine HCl, phenylpropanolamine HCl, and dextromethorphan HBr. J Clin Pharmacol 2001; 41:563-72
26. Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med 2005; 352:1112-20. Erratum in: N Engl J Med 2009; 361:1714
27. Lawrence KR, Adra M, Gillman PK. Serotonin toxicity associated with the use of linezolid: A review of postmarketing data. Clin Infect Dis 2006; 42:1578-83
28. Taylor JJ,Wilson JW, Estes LL. Linezolid and serotonergic drug interactions: A retrospective survey. Clin Infect Dis 2006; 43:180-87
29. US Food and Drug Administration. FDA drug safety communication: Serious CNS reactions possiblewhen linezolid (Zyvox) is given to patients taking certain psychiatric medications. Available at: Http://www.fda.gov/ Drugs/DrugSafety/ ucm265305.htm. Accessed 19 December 2012
30. Cantarini MV, Painter CJ, Gilmore EM, Bolger C, Watkins CL, Hughes AM. Effect of oral linezolid on the pressor response to intravenous tyramine. Br J Clin Pharmacol 2004; 58:470-5
31. Atterson PR, Takacs K, Schlosser MJ. Absence of a pressor response to oral tyramine in conscious telemeterized rats treated with the novel oxazolidinone TR-701: Comparison to linezolid. Presented at: 48th Annual ICAAC/IDSA 46th Annual Meeting (ICAAC/IDSA 2008); 25-28 October 2008;Washington, DC. Poster F1-2067
32. Flanagan S, Bartizal K, Minassian SL, Fang E, Prokocimer P. In vitro, in vivo, and clinical studies of tedizolid to assess the potential for peripheral or central monoamine oxidase interactions. Antimicrob Agents Chemother 2013; 57:3060-6
33. Flanagan S, Minassian SL, Fang E, et al. Lack of MAO inhibition by tedizolid phosphate in clinical and nonclinical studies. Presented at: 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy; 9-12 September 2012; San Francisco, CA. Poster A-1295a.
34. Drusano GL, Liu W, Kulawy R, Louie A. Impact of granulocytes on the antimicrobial effect of tedizolid in a mouse thigh infection model. Antimicrob Agents Chemother 2011; 55:5300-5
35. Das D, Lambert A, Tulkens PM, Muccioli GG, Van Bambeke F. Study of the cellular uptake and subcellular distribution of the oxazolidinone tedizolid (TZD) in murine J774 macrophages: Lack of association with mitochondria. Presented at: 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy; 9-12 September 2012; San Francisco, CA. Poster A-1291
36. Prokocimer P, Bien P, Surber J, et al. Phase 2, randomized, doubleblind, dose-ranging study evaluating the safety, tolerability, population pharmacokinetics, and efficacy of oral torezolid phosphate in patients with complicated skin and skin structure infections. Antimicrob Agents Chemother 2011; 55:583-92
37. Bien P, Bartizal K, Louie A, Drusano G, Prokocimer P. Rationale for the selection of a 200 mg therapeutic dose of oral torezolid phosphate for complicated skin infections. Presented at: 20th European Congress of Clinical Microbiology and Infectious Diseases; 10-13 April 2010; Vienna, Austria. Poster P 1591
38. Fang E, De Anda C, Das A, Prokocimer P. Safety profile of tedizolid phosphate compared to linezolid in a phase 3 ABSSSI study. Presented at: 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy; 9-12 September 2012; San Francisco, CA. Poster L1-1664
39. Prokocimer P, De Anda C, Fang E, Mehra P, Das A. Tedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections: The ESTABLISH-1 randomized trial. JAMA 2013; 309:559-69
40. Lodise TP, Zasowski E, DeAnda C, Fang E. A comparative evaluation of adverse platelet outcomes among patients with acute bacterial skin and skin structure infections receiving tedizolid phosphate and linezolid. Presented at: 50th Infectious Diseases Society of America Annual Meeting; 17-21 October 2012; San Diego, CA. Poster 789
41. US Food and Drug Administration. FDA drug safety communication: FDA limits duration and usage of Samsca (tolvaptan) due to possible liver injury leading to organ transplant or death. Available at: Http:// www.fda.gov/Drugs/ DrugSafety/ucm350062.htm. Accessed 29 August 2013
42. US National Institutes of Health. TR-701 FA vs linezolid for the treatment of acute bacterial skin and skin structure infections. http:// www.clinicaltrials.gov/ct2/show/NCT01421511. Accessed 19 October 2012
43. Fang E, De Anda C, Das A, Prokocimer P. Efficacy and safety results from the ESTABLISH 2 ABSSSI study comparing IV and oral tedizolid phosphate and linezolid. Poster presented at: 23rd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID); 27-30April 2013; Berlin, Germany
44. Muñoz KA, Bien P, Prokocimer P. Assessment of the venous tolerability of torezolid phosphate infused via a peripheral catheter: A novel approach. Presented at: 21st European Congress of Clinical Microbiology and Infectious Diseases; 7-10 May 2011; Milan, Italy. Poster P 1516
45. Herring AR, Williamson JC. Principles of antimicrobial use in older adults. Clin Geriatr Med 2007; 23:481-97
46. Dreskin H, Muñoz KA, Fang E, et al. Safety and pharmacokinetics of single oral administration of tedizolid phosphate in healthy elderly subjects and adult control subjects. Presented at: 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy; 9-12 September 2012; San Francisco, CA. Poster A-1293
47. Hallan SI, Matsushita K, Sang Y, et al. Age and association of kidney measures with mortality and end-stage renal disease. JAMA 2012; 308:2349-60
48. Slatter JG, Stalker DJ, Feenstra KL, et al. Pharmacokinetics, metabolism, and excretion of linezolid following an oral dose of [14C] linezolid to healthy human subjects. Drug Metab Dispos 2001; 29:1136-45
49. Dreskin H, Boyea T, Barker J, Fang E, Prokocimer P. An evaluation of the absorption, metabolism, and excretion of orally administered [14C]-TR-701 FA in healthy subjects. Presented at: 51st Interscience Conference on Antimicrobial Agents and Chemotherapy; 17-20 September 2011; Chicago, IL. Poster A2-033
50. Flanagan S, Morris D, Boyea T, et al. A phase 1 study of intravenously administered tedizolid phosphate in subjects with advanced renal impairment. Presented at: 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy; 9-12 September 2012; San Francisco, CA. Poster A-1294
51. Flanagan S, Boyea T, Dreskin H, et al. A phase 1 study of orally administered tedizolid phosphate in subjects with moderate or severe hepatic impairment. Presented at: 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy; 9-12 September 2012; San Francisco, CA. Poster A-1295
52. Muñoz KA, Dreskin H, Bradley J, et al. Safety and pharmacokinetics after single oral and IV administration of tedizolid phosphate in adolescent patients. Presented at: 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy; 9-12 September 2012; San Francisco, CA. Poster A-1292
53. Wackett A, Nazdryn A, Spitzer E, Singer AJ. MRSA rates and antibiotic susceptibilities from skin and soft tissue cultures in a suburban ED. J Emerg Med 2012; 43:754-7